Leidos Holdings, Inc.: Form 10-Q for the period ended Jul 2, 2021
Filed with the SEC on Aug 3, 2021 and accepted by EDGAR at Aug 3, 2021, 12:37 ET.
Management's discussion and analysis
As filed, 26,287 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion and analysis of Leidos Holdings, Inc.'s ("Leidos") financial condition, results of operations, and quantitative and qualitative discussion about business environment and trends should be read in conjunction with Leidos' condensed consolidated financial statements and related notes.
The following discussion contains forward-looking statements, including statements regarding our intent, belief or current expectations with respect to, among other things, trends affecting our financial condition or results of operations, backlog, our industry, the impact of our merger and acquisition activity, government budgets and spending, our business contingency plans and our ability to recover certain costs through the Coronavirus Aid, Relief and Economic Security Act ("CARES Act"). Such statements are not guarantees of future performance and involve risks and uncertainties, including uncertainties relating to the coronavirus pandemic ("COVID-19") and the actions taken by authorities and us to respond, and actual results may differ materially from those in the forward-looking statements as a result of various factors. Some of these factors include, but are not limited to, the risk factors set forth in our Annual Report on Form 10-K, as updated by the risk factor in this report under Part II, Item 1A. "Risk Factors" and as may be further updated in subsequent filings with the U.S. Securities and Exchange Commission. Due to such uncertainties and risks, you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. We do not undertake any obligation to update these factors or to publicly announce the results of any changes to our forward-looking statements due to future events or developments.
Unless indicated otherwise, references in this report to "we," "us" and "our" refer collectively to Leidos and its consolidated subsidiaries.
Overview
We are a FORTUNE 500® science, engineering and information technology company that provides services and solutions in the defense, intelligence, civil and health markets, both domestically and internationally. We bring domain-specific capability and cross-market innovations to customers in each of these markets by leveraging five technical core competencies: digital modernization, cyber operations, mission software systems, integrated systems and mission operations. Our customers include the U.S. Department of Defense ("DoD"), the U.S. Intelligence Community, the U.S. Department of Homeland Security, the Federal Aviation Administration, the Department of Veterans Affairs and many other U.S. civilian, state and local government agencies as well as foreign government agencies. We operate in three reportable segments: Defense Solutions, Civil and Health. Additionally, we separately present the unallocable costs associated with corporate functions as Corporate.
COVID-19
For the three and six months ended July 2, 2021, COVID-19 did not have a material impact to revenues and operating income. The full extent of the impact of the COVID-19 pandemic on our operational and financial performance, including our ability to execute on programs in the expected timeframe, will depend on future developments, including the duration and spread of the pandemic and the distribution of vaccines, all of which are uncertain and cannot be predicted. While we have been able to make some recoveries, the ultimate timing and amount of recoveries remain uncertain as they will depend on a range of government actions, including each government agency and/or contracting officer's implementation of the authority granted in Section 3610 of the CARES Act, a $2 trillion coronavirus response bill providing widespread emergency relief, including the availability of funds. As a result of Congress passing government fiscal year ("GFY") 2021 appropriations, the relief from the CARES Act has been extended until September 30, 2021.
Business Environment and Trends
U.S. Government Markets
During the three and six months ended July 2, 2021, we generated approximately 86% and 87%, respectively, of our total revenues from contracts with the U.S. government. Accordingly, our business performance is affected by the overall level of U.S. government spending, especially on national security, homeland security and intelligence, and the alignment of our service and product offerings and capabilities with current and future budget priorities of the U.S. government.
Congress received the GFY 2022 President’s Budget Request on May 28, 2021. Congress is working through the appropriations process before the end of the GFY on September 30; however, a continuing resolution is likely. Other potential spending packages include an infrastructure package and a budget reconciliation package.
International Markets
Sales to customers in international markets represented approximately 9% of total revenues for the three and six months ended July 2, 2021. Our international customers include foreign governments and their agencies. Our international business increases our exposure to international markets and the associated international regulatory and geopolitical risks.
Changes in international trade policies, including higher tariffs on imported goods and materials, may increase our procurement costs of certain IT hardware used both on our contracts and for internal use. However, we expect to recover certain portions of these higher tariffs through our cost-plus contracts. While we evaluate the impact of higher tariffs, currently, we do not expect tariffs to have a significant impact to our business.
Results of Operations
The following table summarizes our condensed consolidated results of operations for the periods presented:
(dollars in millions)
| Three Months Ended July 2, 2021 | July 3, 2020 | Dollar change | Percent change | Six Months Ended July 2, 2021 | July 3, 2020 | Dollar change | Percent change | |
|---|---|---|---|---|---|---|---|---|
| Revenues | $3,448 | $2,914 | $534 | 18.3% | $6,763 | $5,803 | $960 | 16.5% |
| Operating income | 269 | 249 | 20 | 8.0% | 577 | 441 | 136 | 30.8% |
| Non-operating expense, net | (46) | (57) | 11 | (19.3)% | (92) | (119) | 27 | (22.7)% |
| Income before income taxes | 223 | 192 | 31 | 16.1% | 485 | 322 | 163 | 50.6% |
| Income tax expense | (53) | (38) | (15) | 39.5% | (110) | (53) | (57) | 107.5% |
| Net income | $170 | $154 | $16 | $375 | $269 | $106 | ||
| Net income attributable to Leidos common stockholders | $169 | $153 | $16 | 10.5% | $374 | $268 | $106 | 39.6% |
| Operating margin | 7.8% | 8.5% | 8.5% | 7.6% |
Segment and Corporate Results
(dollars in millions)
| Defense Solutions | Three Months Ended July 2, 2021 | July 3, 2020 | Dollar change | Percent change | Six Months Ended July 2, 2021 | July 3, 2020 | Dollar change | Percent change |
|---|---|---|---|---|---|---|---|---|
| Revenues | $2,004 | $1,757 | $247 | 14.1% | $3,962 | $3,462 | $500 | 14.4% |
| Operating income | 137 | 119 | 18 | 15.1% | 289 | 214 | 75 | 35.0% |
| Operating margin | 6.8% | 6.8% | 7.3% | 6.2% |
The increase in revenues for the three and six months ended July 2, 2021, as compared to the three and six months ended July 3, 2020, was primarily attributable to program wins, a net increase in volumes on certain programs and total of $37 million and $50 million, respectively, of revenues from the acquisitions of Gibbs & Cox and 1901 Group, partially offset by the completion of certain contracts. In addition, for the three and six months ended July 2, 2021, there was a $29 million and $53 million benefit, respectively, in exchange rate movements.
The increase in operating income for the three and six months ended July 2, 2021, as compared to the three and six months ended July 3, 2020, was primarily due to program wins and a net increase in volumes on certain programs, partially offset by the completion of certain contracts.
LEIDOS HOLDINGS, INC.
(dollars in millions)
| Civil | Three Months Ended July 2, 2021 | July 3, 2020 | Dollar change | Percent change | Six Months Ended July 2, 2021 | July 3, 2020 | Dollar change | Percent change |
|---|---|---|---|---|---|---|---|---|
| Revenues | $799 | $758 | $41 | 5.4% | $1,565 | $1,412 | $153 | 10.8% |
| Operating income | 55 | 78 | (23) | (29.5)% | 129 | 137 | (8) | (5.8)% |
| Operating margin | 6.9% | 10.3% | 8.2% | 9.7% |
The increase in revenues for the three months ended July 2, 2021, as compared to the three months ended July 3, 2020, was primarily attributable to a net increase in program volumes, program wins and a reduction of the negative impacts from COVID-19 experienced during the prior year quarter.
The increase in revenues for the six months ended July 2, 2021, as compared to the six months ended July 3, 2020, was primarily attributable to a net increase of $66 million of revenues related to L3 Harris Technologies' security and detection businesses (the "SD&A Businesses") acquired in the prior year quarter, a net increase in program volumes, program wins and a reduction of the negative impacts from COVID-19 experienced during the prior year quarter.
The decrease in operating income for the three months ended July 2, 2021, as compared to the three months ended July 3, 2020, was primarily due to a net decrease in volumes due to the timing of product deliveries on certain programs.
The decrease in operating income for the six months ended July 2, 2021, as compared to the six months ended July 3, 2020, was primarily attributable to a net decrease in volumes due to the timing of product deliveries on certain programs and increased amortization reflecting one additional month in the current quarter related to intangible assets from the acquisition of the SD&A Businesses, partially offset by a $26 million benefit from an adjustment to legal reserves related to the Mission Support Alliance joint venture during the first quarter of fiscal 2021 and on-contract growth in certain programs.
(dollars in millions)
| Health | Three Months Ended July 2, 2021 | July 3, 2020 | Dollar change | Percent change | Six Months Ended July 2, 2021 | July 3, 2020 | Dollar change | Percent change |
|---|---|---|---|---|---|---|---|---|
| Revenues | $645 | $399 | $246 | 61.7% | $1,236 | $929 | $307 | 33.0% |
| Operating income | 107 | 1 | 106 | NM | 209 | 74 | 135 | 182.4% |
| Operating margin | 16.6% | 0.3% | 16.9% | 8.0% |
The increase in revenues for the three and six months ended July 2, 2021, as compared to the three and six months ended July 3, 2020, was primarily attributable to a net increase in volumes on certain programs, program wins and an approximately $96 million reduction of the negative impacts of COVID-19 experienced during the prior year quarter.
The increase in operating income for the three and six months ended July 2, 2021, as compared to the three and six months ended July 3, 2020, was primarily due to a net increase in volumes on higher margin programs, an approximately $57 million reduction of the negative impacts of COVID-19 experienced during both the prior year quarter and prior year and an $11 million asset impairment charge in the prior year quarter.
(dollars in millions)
| Corporate | Three Months Ended July 2, 2021 | July 3, 2020 | Dollar change | Percent change | Six Months Ended July 2, 2021 | July 3, 2020 | Dollar change | Percent change |
|---|---|---|---|---|---|---|---|---|
| Operating (loss) income | $(30) | $51 | $(81) | (158.8)% | $(50) | $16 | $(66) | NM |
NM - Not Meaningful
The increase in operating loss for the three and six months ended July 2, 2021, as compared to the three and six months ended July 3, 2020, was primarily attributable to an $81 million net gain recognized during the second quarter of fiscal 2020 upon receipt of proceeds related to the VirnetX, Inc. ("VirnetX") legal matter and a decrease in acquisition and integration costs.
Non-Operating Expense, net
Non-operating expense, net for the three months ended July 2, 2021 was $46 million as compared to $57 million for the three months ended July 3, 2020. The change was primarily due to $12 million of debt discount and deferred financing costs written off related to refinancing activities in the prior year.
Non-operating expense, net for the six months ended July 2, 2021 was $92 million as compared to $119 million for the six months ended July 3, 2020. The change was primarily due to $31 million of debt discount and deferred financing costs written off related to refinancing activities in the prior year.
Provision for Income Taxes
For the three months ended July 2, 2021, our effective tax rate was 23.8% compared to 19.8% for the three months ended July 3, 2020. The increase in the effective tax rate was primarily due to an increase to state income taxes and the one-time effects of the increase to the UK tax rate.
For the six months ended July 2, 2021, our effective tax rate was 22.7% compared to 16.5% for the six months ended July 3, 2020. The increase in the effective tax rate was primarily due to a decrease in benefits related to employee stock-based payments, an increase to state income taxes and a prior period release of a valuation allowance related to foreign tax credits.
Bookings and Backlog
We recorded net bookings worth an estimated $3.8 billion and $7.6 billion during the three and six months ended July 2, 2021, as compared to $4.6 billion and $10.2 billion for the three and six months ended July 3, 2020.
The estimated value of our total backlog was as follows:
(in millions)
| Segment | July 2, 2021 Funded | Unfunded | Total | July 3, 2020 Funded | Unfunded | Total |
|---|---|---|---|---|---|---|
| Defense Solutions | $4,293 | $14,154 | $18,447 | $4,275 | $13,779 | $18,054 |
| Civil | 1,608 | 7,493 | 9,101 | 1,695 | 6,634 | 8,329 |
| Health | 1,255 | 4,720 | 5,975 | 1,074 | 3,204 | 4,278 |
| Total | $7,156 | $26,367 | $33,523 | $7,044 | $23,617 | $30,661 |
The change in backlog for the Defense Solutions reportable segment reflects $751 million of backlog acquired as a result of the acquisitions of 1901 Group and Gibbs & Cox.
Backlog represents the estimated amount of future revenues to be recognized under negotiated contracts, both funded and unfunded. Backlog does not include unexercised option periods and future potential task orders expected to be awarded under indefinite delivery/indefinite quantity ("IDIQ") contracts, General Services Administration Schedule or other master agreement contract vehicles, with the exception of certain IDIQ contracts where task orders are not competitively awarded and separately priced but instead are used as a funding mechanism, and where there is a basis for estimating future revenues and funding on future anticipated task orders. Total backlog at July 2, 2021 included a positive impact of $244 million when compared to total backlog at July 3, 2020, due to exchange rate movements in the British pound and Australian dollar when compared to the U.S. dollar. Backlog estimates are subject to change and may be affected by factors including modifications of contracts and foreign currency movements.
Liquidity and Capital Resources
Overview
As of July 2, 2021, we had $338 million in cash and cash equivalents. Additionally, we have an unsecured revolving credit facility which can provide up to $750 million in additional borrowing, if required. As of July 2, 2021, there were no borrowings outstanding under the credit facility and we were in compliance with the related financial covenants.
At July 2, 2021, and January 1, 2021, we had outstanding debt of $5.1 billion and $4.7 billion, respectively. On May 7, 2021, we entered into a Credit Agreement which provided for a senior unsecured term loan facility in an aggregate principal amount of $380 million.
We made principal payments on our long-term debt of $27 million and $53 million during the three and six months ended July 2, 2021, respectively, and $226 million and $228 million during the three and six months ended July 3, 2020, respectively. This activity included required principal payments on our term loans of $24 million and $48 million during the three and six months ended July 2, 2021, and $24 million during the three and six months ended July 3, 2020. During the three and six months ended July 3, 2020 we made additional payments of $2,050 million and $3,975 million, respectively, related to our refinancing activities. The senior unsecured term loans and notes contain financial covenants and customary restrictive covenants. We were in compliance with all covenants as of July 2, 2021.
On July 12, 2021, Leidos, Inc. established a commercial paper program in which we may issue short-term unsecured commercial paper notes not to exceed $750 million and have maturities of up to 397 days from the date of issuance (see "Note 12–Subsequent Events" ).
We paid dividends of $48 million and $98 million during the three and six months ended July 2, 2021, respectively, and $48 million and $99 million during the three and six months ended July 3, 2020, respectively.
During the three and six months ended July 2, 2021, we sold $228 million and $693 million, respectively, of accounts receivable under accounts receivable purchase agreements and received proceeds of $229 million and $693 million, respectively. During the three and six months ended July 3, 2020, we sold $549 million and $1,113 million of accounts receivable under accounts receivable purchase agreements and received proceeds of $549 million and $1,112 million, respectively (see "Note 9–Sale of Accounts Receivable").
Stock repurchases of Leidos common stock may be made on the open market or in privately negotiated transactions with third parties including through accelerated share repurchase agreements. Whether repurchases are made and the timing and actual number of shares repurchased depends on a variety of factors including price, corporate capital requirements, other market conditions and regulatory requirements. The repurchase program may be accelerated, suspended, delayed or discontinued at any time.
During the six months ended July 2, 2021, we made open market repurchases of our common stock for an aggregate purchase price of $100 million. There were no share repurchases made under the Company’s share repurchase program during the second quarter ended July 2, 2021.
COVID-19 has negatively impacted the financial markets and may impact our liquidity; we will continue to assess our liquidity needs as the pandemic evolves.
For the next 12 months, we anticipate that we will be able to meet our liquidity needs, including servicing our debt, through cash generated from operations, available cash balances, sales of accounts receivable and, if needed, borrowings under our revolving credit facility.
Summary of Cash Flows
The following table summarizes cash flow information for the periods presented:
(in millions)
| Three Months Ended July 2, 2021 | July 3, 2020 | Six Months Ended July 2, 2021 | July 3, 2020 | |
|---|---|---|---|---|
| Net cash provided by operating activities | $17 | $422 | $256 | $794 |
| Net cash used in investing activities | (396) | (1,014) | (640) | (2,699) |
| Net cash provided by financing activities | 313 | 709 | 165 | 1,870 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | $(66) | $117 | $(219) | $(35) |
Net cash provided by operating activities decreased $405 million for the three months ended July 2, 2021, when compared to the prior year quarter. The decrease was primarily due to lower sale of accounts receivable of $122 million, higher tax payments of $95 million, timing of customer advance payments of $94 million and the receipt of $85 million of proceeds related to the VirnetX legal matter in the prior year quarter.
Net cash provided by operating activities decreased $538 million for the six months ended July 2, 2021, when compared to the prior year. The decrease was primarily due to lower sale of accounts receivable of $225 million, higher tax payments of $103 million, timing of customer advance payments of $162 million, and the receipt of $85 million of proceeds related to the VirnetX legal matter in the prior year.
Net cash used in investing activities decreased $618 million for the three months ended July 2, 2021, when compared to the prior year quarter primarily due to the larger acquisition made in the prior year quarter for the SD&A Businesses compared to our current quarter acquisition of Gibbs & Cox (see "Note 3–Acquisitions, Goodwill and Intangible Assets") and lower capital expenditures in the current quarter.
Net cash used in investing activities decreased $2,059 million for the six months ended July 2, 2021, when compared to the prior year, primarily due to larger acquisitions made in the prior year for Dynetics and SD&A Businesses compared to our current year acquisitions of 1901 Group and Gibbs & Cox (see "Note 3–Acquisitions, Goodwill and Intangible Assets") and lower capital expenditures in the current year.
Net cash provided by financing activities decreased $396 million for the three months ended July 2, 2021 when compared to the prior year quarter. The change was primarily due to a decrease of approximately $394 million from the net change of proceeds received from the issuance of debt, principal payments and payments for debt issuance costs.
Net cash provided by financing activities decreased $1,705 million for the six months ended July 2, 2021, when compared to the prior year. The change was primarily due to a decrease of approximately $1,656 million from the net change of proceeds received from the issuance of debt, principal payments and payments for debt issuance costs and by $100 million of open market stock repurchases in the current year, partially offset by a $38 million increase in capital contributions received from our non-controlling interest.
Off-Balance Sheet Arrangements
We have outstanding performance guarantees and cross-indemnity agreements in connection with certain aspects of our business. We also have letters of credit outstanding principally related to performance guarantees on contracts and surety bonds outstanding principally related to performance and subcontractor payment bonds as described in "Note 11–Commitments and Contingencies" of the notes to the condensed consolidated financial statements contained within this Quarterly Report on Form 10-Q. These arrangements have not had, and management does not believe it is likely that they will in the future have, a material effect on our liquidity, capital resources, operations or financial condition.
Guarantor and Issuer of Guaranteed Securities
Leidos Holdings, Inc. has fully and unconditionally guaranteed the obligations of its subsidiary, Leidos, Inc., under its $500 million notes due May 2023, $500 million notes due May 2025, $750 million due May 2030 and $1,000 million notes due February 2031 (collectively, "the Notes"). The underlying subsidiaries of Leidos, Inc. do not guarantee these obligations and have been excluded from the financial information presented below.
We have entered into registration rights agreements, pursuant to which we agreed to use reasonable best efforts to file registration statements to permit the exchange of the Notes and related guarantees for registered notes having terms substantially identical thereto, or in the alternative, the registered resale of the Notes and related guarantees under certain circumstances. Pursuant to these registration rights agreements, we filed a Registration Statement on Form S-4 with the Securities and Exchange Commission on May 6, 2021 which was declared effective on May 19, 2021.
The summarized balance sheet for Leidos Holdings, Inc. and Leidos, Inc., net of eliminations, as of July 2, 2021 was as follows (in millions):
Balance Sheet
| Total current assets | $1,791 |
| Goodwill | 4,142 |
| Investments in consolidated subsidiaries | 4,861 |
| Other long-term assets | 1,442 |
| Total assets | $12,236 |
| Total current liabilities | $2,308 |
| Long-term debt, net of current portion | 4,637 |
| Intercompany payables | 1,287 |
| Other long-term liabilities | 888 |
| Total liabilities | 9,120 |
| Total equity | 3,116 |
| Total liabilities and stockholders' equity | $12,236 |
The summarized statements of income for Leidos Holdings, Inc. and Leidos, Inc., net of eliminations, for the three and six months ended July 2, 2021 were as follows (in millions):
Statements of Income
| Three Months Ended | Six Months Ended | |
|---|---|---|
| Revenues, net | $2,296 | $4,516 |
| Operating income | 149 | 346 |
| Net income attributable to Leidos common stockholders | 48 | 144 |
Contractual Obligations and Commitments
We are subject to a number of reviews, investigations, claims, lawsuits, other uncertainties and future obligations related to our business. For a discussion of these items, see "Note 11–Commitments and Contingencies" of the notes to the condensed consolidated financial statements contained within this Quarterly Report on Form 10-Q.
Critical Accounting Policies
There were no material changes to our critical accounting policies, estimates or judgments during the period covered by this report from those discussed in our Annual Report on Form 10-K for the year ended January 1, 2021 except for the elimination of the Income Taxes critical accounting policy.
Recently Adopted and Issued Accounting Standards
For a discussion of these items, see "Note 1–Basis of Presentation and Summary of Significant Accounting Policies" of the notes to the condensed consolidated financial statements contained within this Quarterly Report on Form 10-Q.
Market risk
As filed, 149 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There were no material changes in our market risk exposure from those discussed in our Annual Report on Form 10-K for the year ended January 1, 2021.
Controls and procedures
As filed, 2,108 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our principal executive officer (our Chairman and Chief Executive Officer) and principal financial officer (our Executive Vice President and Chief Financial Officer), has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934) as of July 2, 2021. Based upon that evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the U.S. Securities and Exchange Commission. These disclosure controls and procedures include, without
limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
On May 7, 2021 and January 14, 2021, we completed the acquisitions of Gibbs & Cox and 1901 Group, respectively. In conducting our evaluation of the effectiveness of our internal control over financial reporting, we excluded Gibbs & Cox and 1901 Group from our evaluation for the second quarter of fiscal 2021. As of July 2, 2021, we completed the integration of the SD&A Businesses into our controls over financial reporting.
Other than the foregoing, there have been no changes in our internal control over financial reporting that occurred in the quarterly period covered by this report that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 157 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There were no material changes to the risks described in Part I, Item 1A "Risk Factors" in our Annual Report on Form 10-K for the year ended January 1, 2021.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-07-02. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-04-03 to 2021-07-02 | $3.42bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2021-01-02 to 2021-07-02 | $6.71bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2021-04-03 to 2021-07-02 | $2.95bn | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2021-01-02 to 2021-07-02 | $5.80bn | us-gaap:CostOfRevenue |
| Selling, general and administrative | 3 months2021-04-03 to 2021-07-02 | $224.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2021-01-02 to 2021-07-02 | $392.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2021-04-03 to 2021-07-02 | $269.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2021-01-02 to 2021-07-02 | $577.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2021-04-03 to 2021-07-02 | $53.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2021-01-02 to 2021-07-02 | $110.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-04-03 to 2021-07-02 | $169.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months2021-01-02 to 2021-07-02 | $374.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-04-03 to 2021-07-02 | $1.18 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2021-01-02 to 2021-07-02 | $2.62 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-04-03 to 2021-07-02 | $1.20 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2021-01-02 to 2021-07-02 | $2.65 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2021-04-03 to 2021-07-02 | 143,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2021-01-02 to 2021-07-02 | 143,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2021-01-02 to 2021-07-02 | $256.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2021-01-02 to 2021-07-02 | $47.0m | us-gaap:PaymentsToAcquireProductiveAssets |
| Share repurchases | 3 months2021-04-03 to 2021-07-02 | $0 | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Share repurchases | 6 months2021-01-02 to 2021-07-02 | $100.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2021-07-02 | $338.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-07-02 | $3.26bn | us-gaap:AssetsCurrent |
| Total assets | At period end2021-07-02 | $13.04bn | us-gaap:Assets |
| Current liabilities | At period end2021-07-02 | $3.11bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-07-02 | $8.89bn | us-gaap:Liabilities |
| Current portion of debt | At period end2021-07-02 | $481.0m | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2021-07-02 | $4.10bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001336920-21-000038. Last ingested by Listed: Nov 3, 2026, 11:59 ET. Listed shows no prices and gives no investment advice.